Release Details

LivaNova 10-K filing announcement

March 1, 2017

LivaNova Annual Report Form 10-K filing

London, March 1, 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that it filed an Annual Report on Form 10-K under the U.S. Securities Exchange Act of 1934 for LivaNova for the period January 1, 2016 to December 31, 2016 (“Form 10-K”) with the U.S. Securities Exchange Commission (the “SEC”) on 1 March, 2017. The Form 10-K can be found on the SEC’s website at and in the Investor Relations section of the Company’s website at

A copy of the Form 10-K has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs approximately 4,600 employees.

LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit, or contact:

Catherine Moroz
Company Secretariat
Phone: +44 (0) 203 325 0662

Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262